CUE (Cue Biopharma) Short Percentage of Float


CUE Cue Biopharma Inc CUE
59 GF Score
Price $28.33
GF Value $62.36
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Cue Biopharma Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

CUE vs ALPS, AARD, KLRS: Short Percentage of Float Comparison

For the Biotechnology subindustry, Cue Biopharma's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cue Biopharma Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cue Biopharma's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Cue Biopharma's Short Percentage of Float falls into.


CUE
59GF Score
Cue Biopharma Inc CUE
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cue Biopharma (CUE) Overvalued in 2026?

Based on GuruFocus' analysis, Cue Biopharma stock appears to be undervalued. The current stock price of $28.33 is trading 54.6% below its estimated GF Value™ of $62.36. GuruFocus considers Cue Biopharma to be Possible Value Trap.

Key valuation signals for CUE:

  • Short Percentage of Float:
  • GF Value™: $62.36 vs. price of $28.33 (54.6% below fair value)
  • GF Score™: 59/100 with 3 warning signs

No single metric tells the full story. See the CUE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cue Biopharma Business Description

Other Exchanges 1UC0:Germany
Address 40 Guest Street, Boston, MA, USA, 02135
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
59GF Score

Get the complete analysis for CUE

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$28.33
Price
$62.36
GF Value